M Dorkhan

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. ncbi request reprint Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes
    Mozhgan Dorkhan
    Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Sweden
    Clin Endocrinol (Oxf) 65:35-9. 2006
  2. ncbi request reprint Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes
    M Dorkhan
    Division of Diabetes and Endocrinology, Department of Clinical Sciences, Malmo University Hospital, Lund University, Malmo, Sweden
    J Intern Med 260:125-33. 2006
  3. pmc A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
    Mozhgan Dorkhan
    Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Malmo, Sweden
    Vasc Health Risk Manag 3:721-31. 2007
  4. doi request reprint Independent measures of insulin secretion and insulin sensitivity during the same test: the glucagon-insulin tolerance test
    M Dorkhan
    Division of Diabetes and Endocrinology, Department of Clinical Sciences, Lund University, Malmo University Hospital, Malmo, Sweden
    J Intern Med 264:62-71. 2008
  5. doi request reprint Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone?
    Mozhgan Dorkhan
    Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Malmo S 20502, Sweden
    Diabetes Res Clin Pract 82:340-5. 2008
  6. pmc Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
    Mozhgan Dorkhan
    Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Malmo, Sweden
    Cardiovasc Diabetol 8:15. 2009
  7. pmc Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes
    Magnus Dencker
    Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Sciences, Malmo University Hospital, Malmo, Sweden
    Vasc Health Risk Manag 6:373-82. 2010
  8. pmc Treatment with pioglitazone induced significant, reversible mitral regurgitation
    Mozhgan Dorkhan
    1Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Malmo, Sweden
    Cardiovasc Diabetol 7:12. 2008

Detail Information

Publications8

  1. ncbi request reprint Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes
    Mozhgan Dorkhan
    Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Sweden
    Clin Endocrinol (Oxf) 65:35-9. 2006
    ..Changes in eye protrusion in patients treated with pioglitazone...
  2. ncbi request reprint Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes
    M Dorkhan
    Division of Diabetes and Endocrinology, Department of Clinical Sciences, Malmo University Hospital, Lund University, Malmo, Sweden
    J Intern Med 260:125-33. 2006
    ....
  3. pmc A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
    Mozhgan Dorkhan
    Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Malmo, Sweden
    Vasc Health Risk Manag 3:721-31. 2007
    ....
  4. doi request reprint Independent measures of insulin secretion and insulin sensitivity during the same test: the glucagon-insulin tolerance test
    M Dorkhan
    Division of Diabetes and Endocrinology, Department of Clinical Sciences, Lund University, Malmo University Hospital, Malmo, Sweden
    J Intern Med 264:62-71. 2008
    ..e. combined glucagon-stimulated C-peptide test and insulin tolerance test (GITT)...
  5. doi request reprint Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone?
    Mozhgan Dorkhan
    Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Malmo S 20502, Sweden
    Diabetes Res Clin Pract 82:340-5. 2008
    ..While metformin is the first line treatment in type 2 diabetes, the best way to escalate therapy is not always clear, particularly whether to add one or two oral agents or to introduce insulin...
  6. pmc Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
    Mozhgan Dorkhan
    Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Malmo, Sweden
    Cardiovasc Diabetol 8:15. 2009
    ..The present study evaluated the effect of pioglitazone or insulin glargine on cardiac function and size as well as on surrogate markers of fluid retention such as weight, haemoglobin and natriuretic peptides...
  7. pmc Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes
    Magnus Dencker
    Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Sciences, Malmo University Hospital, Malmo, Sweden
    Vasc Health Risk Manag 6:373-82. 2010
    ..There were significant differences in BNP and NT-proBNP levels between the group with normal left ventricular diastolic function and the group with abnormal diastolic function...
  8. pmc Treatment with pioglitazone induced significant, reversible mitral regurgitation
    Mozhgan Dorkhan
    1Department of Clinical Sciences, Division of Diabetes and Endocrinology, Lund University, Malmo University Hospital, Malmo, Sweden
    Cardiovasc Diabetol 7:12. 2008
    ..It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs...